The Anthropometric Detective and His Racial Clues
By Ava Kofman,
The Public Domain Review
| 02. 24. 2016
Untitled Document
A complex pattern is capable of suggesting various readings, as the figuring on a wall-paper may suggest a variety of forms and faces to those who have such fancies. — Francis Galton, Finger Prints, 1892
By the time Arthur Conan Doyle published “The Adventure of the Norwood Builder” in The Strand Magazine in 1903, the reputation of the fingerprint as a powerful and “self-evident” forensic technology — one that could be used in a court of law to prove a suspect’s guilt — was on the rise. In 1902, a fingerprint was accepted in an English court as evidence for a burglar’s presence at the scene of the crime. By 1904, Scotland Yard was processing as many as three hundred fingerprint cards every week. Precisely because the fingerprint’s authoritative status was taken for granted, Conan Doyle’s fictional detective Sherlock Holmes sought to undermine it. In “Norwood Builder”, Holmes discovers that the fingerprint in question does not belong to the suspect, but is, instead, a forged print used to frame him.
Although Holmes published on fingerprints in the anthropological...
Related Articles
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
By Robert Resta, The DNA Exchange | 07.22.2024
Medical geneticists and genetic counselors have an often complicated and at times tense relationship with people with disabilities, their families, advocates, and scholars. Geneticists are strong advocates and supporters for all of their patients, regardless of their abilities and disabilities...
By Katherine Bourzac, Nature | 07.10.2024
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...